Mocetinostat
| Title | Journal |
|---|---|
| Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms. | Toxicological sciences : an official journal of the Society of Toxicology 20160901 |
| Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. | Oncotarget 20151020 |
| Natural indoles, indole-3-carbinol and 3,3'-diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression. | Toxicology and applied pharmacology 20140101 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. | Journal of medicinal chemistry 20121126 |
| Novel agents in Hodgkin lymphoma. | Current oncology reports 20121001 |
| An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. | Cancer chemotherapy and pharmacology 20120601 |
| Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. | Cancer biology & therapy 20120601 |
| Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. | Circulation research 20120302 |
| Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. | The Lancet. Oncology 20111201 |
| Histone deacetylase inhibitors and Hodgkin's lymphoma. | The Lancet. Oncology 20111201 |
| Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. | Journal of medicinal chemistry 20110714 |
| The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. | Oncogene 20110707 |
| Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells. | Cancer science 20110601 |
| Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. | Expert opinion on investigational drugs 20110601 |
| Clinical development of panobinostat in classical Hodgkin's lymphoma. | Expert review of hematology 20110601 |
| Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. | Cytotherapy 20110501 |
| Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy. | Bioorganic & medicinal chemistry letters 20110101 |
| Interpreting clinical assays for histone deacetylase inhibitors. | Cancer management and research 20110101 |
| Histone deacetylase inhibitors in Hodgkin lymphoma. | Investigational new drugs 20101201 |
| Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. | Investigational new drugs 20101201 |
| The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. | British journal of haematology 20101101 |
| Histone deacetylase inhibitors in the treatment of lymphoma. | Discovery medicine 20101101 |
| The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. | Oncotarget 20101101 |
| The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Autophagy 20101001 |
| The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity. | Molecular pharmacology 20100901 |
| The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100801 |
| Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. | Molecular cancer therapeutics 20100801 |
| The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. | Molecular cancer therapeutics 20100501 |
| [New approach to determine the pharmacodynamic effects of histone deacetylases inhibitors]. | Pharmazie in unserer Zeit 20100501 |
| Effect of antioxidants on airway smooth muscle contraction: action of lipoic acid and some of its novel derivatives on guinea pig tracheal smooth muscle. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20100301 |
| Effect of endogenous and synthetic antioxidants on hydrogen peroxide-induced guinea-pig colon contraction. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20100301 |
| Chemical phylogenetics of histone deacetylases. | Nature chemical biology 20100301 |
| Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. | Journal of hematology & oncology 20100101 |
| Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. | British journal of haematology 20091101 |
| Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20091001 |
| Clinical studies of histone deacetylase inhibitors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. | Anti-cancer drugs 20090601 |
| A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. | International journal of radiation oncology, biology, physics 20090301 |
| SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103). | Bioorganic & medicinal chemistry letters 20090201 |
| Sulfamides as novel histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20090115 |
| New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. | Journal of hematology & oncology 20090101 |
| Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. | International immunopharmacology 20081220 |
| Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. | Blood 20080815 |
| Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor. | Expert opinion on investigational drugs 20080801 |
| Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. | Journal of medicinal chemistry 20080724 |
| Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080601 |
| Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420 |
| MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. | Molecular cancer therapeutics 20080401 |
| Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. | Bioorganic & medicinal chemistry letters 20080315 |
| Histone deacetylase inhibitors in lymphoma and solid malignancies. | Expert review of anticancer therapy 20080301 |
| Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors. | Bioorganic & medicinal chemistry letters 20080201 |
| Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. | The Biochemical journal 20080115 |
| Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. | International journal of cancer 20070901 |
| Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. | Current opinion in investigational drugs (London, England : 2000) 20070601 |